European Pharmacovigilance Congress 2026
EnglishEnglishConference overview
Become sponsor of European Pharmacovigilance Congress 2026, click here
The European Pharmacovigilance Congress, organized by Pharma Education Center, is recognized as one of the most important and appreciated global pharmacovigilance conferences thanks to its top-tier scientific content.
The high value of this year`s program is assured by the contribution of the key opinion leaders, experts and scientists included in the Scientific Advisory Group (SAG).
In addition, we are delighted to announce the new scientific partnership with the renowned Department of Pharmacological and Biomolecular Sciences of the Milan University (Università degli Studi di Milano) and the confirmation of collaboration with the Institute of Pharmacovigilance.
The EUPV Scientific Advisory Group has very clear that pharmacovigilance main pillars are:
• Safety Science – Regulatory compliance – Operational excellence
• Implementation of new technologies – Effective communication
All these aspects are reflected in the agenda of this year’s congress.
The EUPV congress gathers PV professionals at all career levels, including key decision makers (e.g. VPs, Executives and Directors) interested in the always evolving pharmacovigilance world and its new trends, since they are always looking for new ideas to implement more efficient and effective strategies and tools for their departments.
EUPV congress is the forum where all PV stakeholders from all over the world meet and exchange ideas.
PLEASE NOTE:
Ticket options labeled ‘+ Visa’ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
ANNUAL EUPV BOOKLET
The 3rd European Pharmacovigilance Congress: speaker abstracts 2019
The 4th European Pharmacovigilance Congress: speaker abstracts 2020
The 5th European Pharmacovigilance Congress: speaker abstracts 2021
The 6th European Pharmacovigilance Congress: speaker abstracts 2022
The 7th European Pharmacovigilance Congress: speaker abstracts 2023
The 8th European Pharmacovigilance Congress: speaker abstracts 2024
The 9th European Pharmacovigilance Congress: speaker abstracts 2025
Published by Sage Journals, visit their website here
Format del congresso
The European Pharmacovigilance Congress 2026 will be a mixed event!
November 18 | Virtual (9.00 – 5.30 pm)
November 19 | Virtual (9.00 – 6.00 pm)
December 3 | Milan* (3.00 – 7.00 pm) + Networking Aperitivo (7.00 – 9.00 pm)
December 4 | Milan* (9.15 – 5.30 pm)
* at NH Milan Congress Centre
NETWORKING APERITIVO December 3 (7.00 – 9.00 pm)
At the conference venue, PEC organizes a Networking Aperitivo that will take place together with interesting workshops. Reserve your place to meet and network with your colleagues and experts: Networking Aperitivo
The intense, scientific interaction between speakers and delegates is a further invaluable plus of the event:
– 27 Topics
– 24 round tables
– 7 virtual parallel sessions
– 1 LECTIO Magistralis
– 3 F2F parallel workshops
Why attend?
- Learn about the latest Pharmacovigilance trends and updates
- Share experiences and solutions at a leading European event
- Forge new collaborations with key decision makers
- Networking through the virtual platform with Pharma Companies Delegates and Speakers
Who should attend?
- Pharma, Biotech and Medical Devices Industries
- Pharmacovigilance Associations
- Regulatory Bodies
- CROs and CMOs
- Clinical Research Sites
- Data Management Companies
- Software Development Companies
- University Faculties
- PV Consultant Societies
AGENDA 2026
FEATURED TOPICS:
• DEVELOPMENTAL SAFETY FROM FIRST IN HUMAN TO MARKETING AUTHORIZATION APPLICATION
• PREDICT, PREVENT, PROTECT: TRANSLATIONAL SAFETY AS THE CATALYST FOR SMARTER RISK STRATEGIES
• SAFETY OF GENE THERAPIES AND RARE DISEASES
• SYNTHETIC DATA IN PHARMACOVIGILANCE: OPPORTUNITIES, RISKS AND REGULATORY REALITY
• NON-EU PV REQUIREMENTS (Africa, Asia, Americas, UK)
• DECISIONS THAT MATTER: REAL LIFE IMPACT OF DRUG SAFETY WORK
• SAFETY OF MEDICINES IN EARLY ACCESS PROGRAM
• SAFETY OF DRUGS USED IN HEPATIC RARE DISEASES
• SAFETY ASPECTS OF NEW PRODUCTS USED FOR THE TREATMENT OF INFLAMMATORY DISORDERS
• IMPACT OF NEW REGULATIONS AND GUIDELINES ON PV OPERATIONS
• REGULATORY REQUIREMENTS AND PRACTICAL EXEMPLES FOR IMPLEMENTING AI IN PV
• MEDICAL DEVICES & COMBINATION PRODUCTS SAFETY
• SAFETY INFORMATION FROM PATIENTS´PERSPECTIVE
• COSMETOVIGILANCE AND SAFETY OF NUTRACEUTICALS PRODUCTS
• EMA COMPUTERIZED SYSTEMS UPDATES
• ECOPHARMACOVIGILANCE
• PHARMACOEPIDEMIOLOGY AND REAL-WORLD EVIDENCE IN PHARMACOVIGILANCE: FROM SIGNAL TO DECISION
• RISK MANAGEMENT SYSTEMS
• WHAT IS AI AND ITS IMPLEMENTATION IN CASE PROCESSING
• HUMAN MACHINE INTERFACE IN PV
• SIGNAL DETECTION AND MANAGEMENT: THE USE OF RWD/RWE, THE USE OF AI AND POSSIBLE LIMITATIONS
• EFFICIENCY AND EFFECTIVENESS IN A RAPIDLY CHANGING PV LANDSCAPE
• MASTERING SAUDI/GCC PHARMACOVIGILANCE 2026
• PV AUDIT & INSPECTION
NOVEMBER 18 | VIRTUAL
In progress..
Translational safety is the science of predicting adverse reactions that may occur in humans by integrating preclinical and clinical data across drug development. Early and reliable prediction of risks associated with an investigational medicinal product can increase the likelihood of successful development and, most importantly, safeguards subjects participating in clinical trials.
In progress..
Pharmacovigilance outside the EU presents a highly dynamic regulatory landscape, shaped by local public‑health priorities and evolving legal frameworks. This session will take us across Asia and Africa, highlighting how global principles translate into regional practice. Pharmacovigilance systems must be reviewed to ensure alignment with these requirements.
The era of AI has paved the road to completely new possibilities that would have been unthinkable only a few years ago. This session looks into the near future by discussing the use of artificially generated datasets that mimic real drug-safety data.
While the methodologies to assess the risks of medicinal products are common throughout all therapeutic areas, each of them requires specific considerations. This session focuses on important safety aspects that have required investigation for new products indicated in inflammatory disorders
In progress..
SAFETY OF DRUGS USED IN HEPATIC RARE DISEASES (A DISCUSSION AT THE EUROPEAN PARLIAMENT)
A unique opportunity to hear first‑hand about a discussion held at one of Europe’s most important institutions, presented directly by the speaker involved sharing information that can be publicly disclosed.
SAFETY OF DRUGS USED IN HEPATIC RARE DISEASES (A DISCUSSION AT THE EUROPEAN PARLIAMENT)
A unique opportunity to hear first‑hand about a discussion held at one of Europe’s most important institutions, presented directly by the speaker involved sharing information that can be publicly disclosed.
NOVEMBER 19 | VIRTUAL
In progress..
In progress..
In progress..
AI has been a key buzzword in pharmacovigilance over recent years, yet its practical implementation remains a challenge. This session focuses on methodologies and real‑world examples that illustrate how AI can be effectively implemented in pharmacovigilance practice.
In progress..
In progress..
Pharmacovigilance professionals are often not fully aware of closely related disciplines, such as cosmetics and nutraceutical safety, and of the potential impact these products may have on drug safety. This session aims to provide an overview of these areas
All pharmacovigilance stakeholders, including regulators, are continuously enhancing their digital tools. This session enables participants to stay up to date with changes in EMA systems, such as EudraVigilance and the Clinical Trials Information System (CTIS).
In progress..
DECEMBER 3 | MILAN
The aim of pharmacovigilance is to identify the most important risks associated with a medicinal product and to minimise them, ensuring a positive benefit–risk balance. This session provides insights into how to establish an effective risk management system, including in particularly challenging situations.
The unprecedented volume of patient data available today offers new opportunities to transform data into meaningful evidence. Pharmacoepidemiology and real‑world evidence play a central role in identifying, quantifying, and characterizing risks, supporting more informed and robust regulatory decision‑making.
Many of us talk about AI without realizing it encompasses a range of different technologies, each with distinct characteristics, advantages, and limitations. This session introduces the fundamentals of AI and illustrates its practical application through a real‑life example in case processing.
BY IVIGEE
DECEMBER 4 | MILAN
In progress..
Pharmacovigilance is grounded in scientific disciplines such as biology and pharmacology, which underpin medicine safety from non‑clinical research through clinical development and shape risk management strategies. This session offers real‑world insights into the value of applying scientific principles to drug safety.
BY BAUPHARMA
Applying artificial intelligence to real‑world evidence is one of today’s most prominent topics. But what do regulators think? This session offers a rare opportunity to hear directly from PRAC members and leading scientists on how AI can be used to transform real‑world data into robust evidence for signal detection and management.
Featured presenters:
- Elena Alcaraz , EU/UK QPPV, Strategic Advisor | PrimeVigilance
- Mercedina del Papa, EU/UK QPPV, Strategic Advisor | PrimeVigilance
The session that traditionally closes the EU PV Congress is also one of its most important. Compliance -and the successful outcome of audits and inspections- represents the true “license to operate” in pharmacovigilance and across the pharmaceutical industry.
Scientific Advisory Group 2026
Felix Arellano
Senior Vice President and the Global Head of Safety & Risk Management | Roche
Ayman Ayoub
Vice President Safety Evaluation and Risk Management | GSK
Mattia Calissano
VP, Medical | SSI Strategy
Gian Nicola Castiglione
Pharmacovigilance Consultant, SIMeF ETS Board member, Past Head of Global Pharmacovigilance and EU-UK QPPV, Pharmacovigilance trainer
Manuela Casula
Associate Professor at Department of Pharmacological and Biomolecular Sciences | University of Milan
Mircea Ciuca
Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance
Giovanni Furlan
Head Medical Safety Operations | Sandoz
Calin A. Lungu
DDCS S.A., CEO
Hrvoje Maček
VP Pharmacovigilance Services | Clingen
Valentina Mancini
Senior Director Pharmacovigilance, QPPV | Shionogi Europe
Arduino Mangoni
Strategic Professor in Clinical Pharmacology | Flinders University, Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia
Jan Petracek
CEO | iVigee, Director | Institute of Pharmacovigilance
Marco Sardella
Chief Pharmacovigilance Officer & EU-UK QPPV| ADIENNE Pharma & Biotech
Ivana Šutalo
Innovative Products, Business Unit Lead / EU QPPV / LCPPV Croatia | PrimeVigilance Ltd.
SPEAKERS 2026 IN PROGRESS
Ana Sofia Martins
PRAC Member | INFARMED, I.P. – Portugal
Elena Giovani
Head of the GVP Inspection Office | AIFA (Tbc)
Amelia Cupelli
Pharmacologist, Italian Medicines Agency (AIFA), EMA PRAC Member, Italy
Pilar Rayón
PRAC – AEMPS Spain
Sophia Trantza
Senior Pharmacovigilance Expert, former PRAC Member Greece
Elena Prokofyeva
Head of Clinical Trial Safety Unit, Department of Pharmacovigilance, DG POST | FAMHP – Belgium
Lembit Rägo
Secretary-General | Council for International Organizations of Medical Sciences (CIOMS) – Switzerland
Ursula Kirchmayer
Pharmacoepidemiologist at the Department of Epidemiology | Lazio regional health service
Fazil Afzal
Senior Medical Assessor at Medicines and Healthcare products Regulatory Agency (MHRA) – Uk (tbc)
Michelle English
GCP/PV Inspector | HPRA – Ireland
Oanh Dang
Regulatory Science and Applied Research Lead | Food and Drug Administration (FDA) – USA
Marko Korenjak
President of the European Liver Patients ( ELPA), member of HMA management board of EMA – Slovenia
Maia Uusküla
Head of the Department of Post-Authorisation Safety | State Agency of Medicines, Estonia
Zane Neikena
PRAC – Latvia
Jens-Ulrich Stegmann
Senior Vice President, Head Clinical Safety and Pharmacovigilance and EU QPPV | GSK – Belgium
Jonathan Sutch
Principal Technical Specialist & Scheme Manager | BSI Group – UK
Axelle Mutezinkwano
Pharmacovigilance Analyst Team Lead | Rwanda Food and Drugs Authority
Annalisa Capuano
Full Professor of Pharmacology – Department of Experimental Medicine | University of Campania “L. Vanvitelli” – Italy
Kaori Nomura
Associate Professor | Fukushima Medical University – Japan
Andrew Bate
VP, Head of Safety Innovation & Analytics | GSK – Uk
Salvo Leone
General Director | Patient’s Association AMICI, Italy
Emanuele Lettieri
Full Professor | Politecnico of Milan, Italy
Margherita D’Antuono
EU-UK QPPV | Piramal Critical Care
Vicky Edwards
Vice President, Cross Therapeutic Area Safety Science, Global Patient Safety| Abbvie – UK
Anna Lombardo
Researcher | Istituto di Ricerche Farmacologiche Mario Negri IRCCS – Italy
Giovanna Paolone
Associate Professor of Pharmacology – Department of diagnostics and public health | University of Verona – Italy
Emanuela Corsini
Professor of Toxicology at Department of Pharmacological and Biomolecular Sciences ‘Rodolfo Paoletti’ | University of Milan
Barbara De Bernardi
EU & UK Pharmacovigilance Qualified Person, VP, Head of Global QPPV Office Worldwide Medical & Safety | Pfizer – Italy
Helaine Capucho
Access Director | Interfarma – Brazil
Ahmed Diaa Eldin
CEO | Baupharma – Czech Republic
Marie-Laure Kurzinger
Associate VP, Head of Pharmacoepidemiology -General Medicines, Pharmacovigilance and Patient Safety | Sanofi – France
Rajat Mohindra
Principal Medical Director Personalized Healthcare Safety | F.Hoffmann – La Roche – Switzerland
Adrian Roth
Principal Scientific Director Precision Safety | Roche – Switzerland
Ilaria Grisoni
Exec. Dir., Head of International QPPV Office, EEA QPPV | Jazz Pharmaceuticals – Italy
Michael Von Forstner
Managing Director | Mesa Laubela Consulting – Switzerland
Yiannoula Koulla
Patient Expert, Member of the EMA PRAC
Klaudija Marijanovic Barac
Associate VP, EU QPPV Deputy | Eli Lilly Hrvatska d.o.o. – Croatia
Daniela Gramaglia
Associate Director Medical Device Safety | Bayer
Alberto Gramaccioli
Director of Quality Management and Inspection | Pfizer
Maria Beatrice Panico
Chief Medical Officer | Scendea – UK
Maddalena Lino
Safety Risk Lead Director | Pfizer – Italy
Daniela Marcozzi
Head of Corporate Clinical Safety, Pharmacovigilance and R&D Compliance – Company Representative for Competent Health Authorities | Fidia Farmaceutici – Italy
Bogdana Ioana Balas
Group Medical Director | F. Hoffmann – La Roche Ltd – Switzerland
Lucia Biagiotti
Safety & Vigilance – BU Director | PL Italia
Alexandru Mihai Bica
Head of Early Development Safety | CSL Behring – Germany
Mehmet Burcu
Sr. Director, Epidemiology | Merck & Co., Inc., Rahway – NJ, USA
Marie-Pierre Caby-Tosi
Executive Director, EEA/UK QPPV, Head of EMEA PV Clinical Safety & Pharmacovigilance | Moderna – France
Katerina Georgousaki
Regulatory Affairs Manager | ELAIS-Unilever Hellas S.A. – Greece
Ramona Grigorescu
Senior Medical Monitor | Danone – Holland
Sadia Halim
SERM Medical Director | GSK – Uk
Daniel Hyde
Associate Director, Pharmacovigilance Operations | Clinigen – UK
Wojciech Masełbas
SERM Medical Director | Gsk – Poland
James Milligan
Vice President | SSI – UK
Darmendra Ramcharran
Sr Director, Safety & Quantitative Innovation | GSK – USA
Hendrik Šuvalov
PhD Student in Health Informatics | University of Tartu – Estonia
Alina Tudor
Senior Director, Pharmacovigilance | Kyowa Kirin International plc. – UK
Hans-Joerg Roemming
Executive Director, Head of RQS Information, Systems & Insights | Merck Healthcare KGaA
MEDIA PARTNER/COLLABORATIONS/SPONSORS 2026 – in progress
Sage Publishing
Scientific Media Partner
Sage Publishing
Scientific Media Partner
Published by Sage Publishing, Therapeutic Advances in Drug Safety (Impact Factor: 3.4) is an international peer-reviewed Open Access journal, delivering the highest quality original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in drug safety, providing an online forum for rapid dissemination of recent research and perspectives in this area.
As the official Media Partner of the European Pharmacovigilance Congress, Therapeutic Advances in Drug Safety will be publishing an online abstract supplement which will be free to access online.
For more information:
E-mail: shasha.sharief@sagepub.co.uk
Twitter: @TADrugSafety
Visit our website »
Institute of Pharmacovigilance
Collaboration
Institute of Pharmacovigilance
Collaboration
Founded in 2015, the Institute of Pharmacovigilance (IPV) is a not-for-profit, non-governmental global organization with a clear goal – to elevate the pharmacovigilance industry by competency and seniority certification.
In 2020, IPV partnered with the International Society of Pharmacovigilance (ISoP) to develop the Global Pharmacovigilance Professional Certification (GPPC), creating a globally recognized standard for PV professionals. The certification works with competency standards including knowledge, skills and attitudes suitable for every role in pharmacovigilance.
Committed to continuous innovation, IPV regularly updates its programs to reflect the latest advancements, ensuring certified professionals have practical knowledge and skills they can apply in their jobs immediately.
Visit our website »
Università degli Studi di Milano – Dipartimento di Scienze Farmacologiche e Biomolecolari
Scientific Partnership
Università degli Studi di Milano – Dipartimento di Scienze Farmacologiche e Biomolecolari
Scientific Partnership
Il Dipartimento di Scienze Farmacologiche e Biomolecolari “Rodolfo Paoletti” (DiSFeB), nominato Dipartimento di Eccellenza 2023-2027, nasce il 27 aprile 2012 dall’aggregazione di settori scientifico disciplinari con comuni interessi di ricerca scientifica di alto profilo, e assicura un’equilibrata valorizzazione di tutti i settori scientifico-disciplinari che vi afferiscono. Il DiSFeB mira a consolidare il suo ruolo chiave nelle attività didattiche e di ricerca, e a rinnovare il suo portfolio di competenze tecnico-scientifiche a beneficio della società, contribuendo nel campo delle scienze biologiche applicate alla salute umana, alla prevenzione delle malattie e alla progettazione di farmaci e prodotti per la salute.
Visit our website »
Baupharma
Silver Sponsor
Baupharma
Silver Sponsor
Baupharma, headquartered in Prague, is a premier pharmaceutical service provider with over 25 years of industry experience. Our international team offers comprehensive services—including pharmacovigilance, regulatory affairs, medical writing, batch release and distribution, translations, and clinical research—across the EU, MENA region, CIS, Africa, USA, LATAM, and beyond. With offices in Czech Republic, Saudi Arabia, UAE and Egypt, we ensure efficient project management and collaboration, delivering tailored solutions that meet the unique needs of each market.
Visit our website »
Eureka InfoMed
Exhibitor
Eureka InfoMed
Exhibitor
Eureka InfoMed – Your Team to Growth
We make Pharmacovigilance work — reliably, efficiently, and with purpose.
Eureka InfoMed is a trusted partner delivering end‑to‑end operational support across Pharmacovigilance, Medical Information, and Quality.
We combine operational excellence with a pragmatic, partnership‑driven approach to turn complexity into compliant, efficient, and scalable processes.
Within these areas, we support pharmaceutical and biotech companies through services including Quality Management Systems, Quality Assurance activities, and Pharmacovigilance audits, helping them strengthen compliance, mitigate risk, and optimize operations in a constantly evolving regulatory environment.
We don’t believe in one‑size‑fits‑all solutions.
Whether you are building, strengthening, or transforming your Pharmacovigilance organization, Eureka InfoMed works side by side with you, acting as an extension of your team and providing expertise that grows with your needs and strategic objectives.
Visit our website »
Insuvia
Exhibitor
Insuvia
Exhibitor
Insuvia is designed to act as a pharmacovigilance unit for pharmaceutical companies in those countries and regions, where they have no internal structures or decide to focus their resources on commercial activities. In this context, we provide the regional EU and country-level expertise to solve all pharmacovigilance challenges that pharmaceutical companies encounter while commercializing their products.
Visit our website »
iVigee
Platinum Sponsor
iVigee
Platinum Sponsor
iVigee is a leading pharmacovigilance services and technology company focused on creating simple, powerful, and elegant drug safety solutions that span the entire drug safety life cycle.
We combine years of experience with the latest innovative AI technologies to create the ‘instant pharmacovigilance department’, deployable anywhere, on-demand.
Our teams support clients around the world with progressive pharmacovigilance and data management requirements from our strategic bases in Central Europe and the US East Coast.
iVigee: Simple. Powerful. Elegant.
Visit our website »
Max Application
Exhibitor
Max Application
Exhibitor
SafetyDrugs, developed by Max Application, an Abacus company, is a pharmacovigilance safety database managing the lifecycle of ICSRs from clinical trials and post-marketing sources. Designed in compliance with ICH E2B(R3), GVP and GDPR, it meets EMA, FDA and MHRA requirements. The platform enables automated case transmission and regulatory reporting (PSUR, PBRER, DSUR), ensuring data integrity, inspection readiness and full compliance. The offering is completed by the Business Intelligence module for Signal Detection and by the newly developed Chronisia, which automatically calculates regulatory deadlines (e.g. PSUR, RMP, MA renewal) enables task assignment and reduces risk of delays and non-compliance.
Visit our website »
PrimeVigilance
Gold Plus Sponsor
PrimeVigilance
Gold Plus Sponsor
PrimeVigilance, an Ergomed company, has grown to become the leading Pharmacovigilance specialist company, delivering global solutions for clinical safety and post-marketing pharmacovigilance and medical information from our operational hubs based in Europe, the USA, and Japan. Our extensive experience enables us to offer a comprehensive, top-quality, cost-effective, and innovative safety solution. Our flexible approach, tailor-made to work with clients, allows us to deliver the services that meet your clinical and post-marketing needs. PrimeVigilance provides pharmacovigilance solutions to over 300 clients who distribute their products worldwide. PrimeVigilance manages a global Pharmacovigilance system with a choice of leading drug safety databases, stretching to more than 100 countries.
Visit our website »
ProductLife Group
Exhibitor
ProductLife Group
Exhibitor
ProductLife Group’s mission is to improve human health by delivering regulatory compliance services that support the safe and effective use of healthcare products and solutions.
For more than 30 years, PLG has supported clients throughout the entire product lifecycle, combining local expertise with a global reach spanning more than 150 countries. The Group provides consulting and outsourcing services across regulatory affairs, quality and compliance, market access, pharmacovigilance, and medical information, covering both established products and innovative therapeutics and diagnostics.
Committed to continuously improving the value delivered to patients and customers, PLG fosters long-term partnerships built on innovation, flexibility, and cost efficiency.
Visit our website »
PVpharm
Gold Sponsor
PVpharm
Gold Sponsor
Pharmacovigilance, Clinical Safety, Regulatory and Quality Solutions for the pharmaceutical industry.
PVpharm provides services to Marketing Authorisation Holders, Sponsors of Clinical Trials and other Life science service providers.
Our objective is to help the Pharmaceutical industry to comply with Pharmacovigilance, Clinical safety, Regulatory and Quality requirements. We provide global, professional, quick, and flexible solutions to complex, specialized needs.
Our specialities include Pharmacovigilance and Clinical Safety services, Regulatory affairs, Medical Services, EU-QPPV and Local contact person for pharmacovigilance, Pharmacovigilance and GCP Audits, EudraVigilance compliance, CTIS support, Pharmacovigilance training, including EVWeb and XEVMPD (eXtended EudraVigilance Medicinal Product Dictionary) training, Signal Detection and Signal Management using EVDAS, IDMP implementation preparation, and data management.
We provide services for drugs, devices, veterinary, food supplements and cosmetics.
We do also provide GxP support and provide GMP specialized audits.
Visit our website »
Become a sponsor
Don’t miss the chance to be a European Pharmacovigilance Congress 2026 sponsor!
Contact us to learn about our sponsorship packages, you will have the opportunity to:
• Deliver a talk in person or online
• Conduct a parallel session during the day in Milan
• Network and connect with your target customers
Check out our sponsorship opportunities here: Become EUPV Sponsor
Conference Venue
Step 1
On November 18-19 the event will be VIRTUAL to grant you the possibility of joining the conference even from your office or home, wherever you may be. We have organized a true virtual location, a space where you will be able to:
- Follow the live streaming of the congress, listen to experts and opinion makers and be informed about latest trends and technological breakthroughs in drug safety
- Visit the VIRTUAL EXHIBITION AREA and all the stands of our sponsors
- Join Q&A times and round tables to discuss the current hot topics in the field
- Chat with our sponsors and learn about new technologies and services to ease your daily work and increase the performance
Step 2
Let’s finally meet face to face in Milan on December 3-4! A great chance to meet in person the EUPV experts and colleagues. A great chance to meet in person the EUPV experts and colleagues. The conference will be hosted in the wonderful spaces of NH Milano Congress Centre, in Assago, Milan.
NETWORKING APERITIVO December 3, 2026 (NH Milano Congress Centre, in Assago, Milan)
–> If you would like to attend the Networking Aperitivo, please save your spot here: Networking Aperitivo
PLEASE NOTE:
Ticket options labeled ‘+ Visa’ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
By plane
From Malpensa Airport:
-
- take the bus to the central station, then the subway towards Assago Milanofiori Forum
- take the express train from Malpensa to the Cadorna station, then the Green subway in the direction of Assago Milanofiori Forum.
From Linate Airport:
take the bus to San Babila station, then the subway towards Assago Milanofiori Forum.
By train
From Centrale or Cadorna train station, take green line subway to Assago Milanofiori Forum.
By tram
From Piazza del Duomo:
take the red subway line towards RHO FIERAMILANO and change at CADORNA. Take the green line towards ASSAGO MILANOFIORI FORUM and get off at the Assago Milanofiori Forum stop. Walk for about 7 minutes to reach the hotel.
All the past editions
Conference overview
Become sponsor of European Pharmacovigilance Congress 2026, click here
The European Pharmacovigilance Congress, organized by Pharma Education Center, is recognized as one of the most important and appreciated global pharmacovigilance conferences thanks to its top-tier scientific content.
The high value of this year`s program is assured by the contribution of the key opinion leaders, experts and scientists included in the Scientific Advisory Group (SAG).
In addition, we are delighted to announce the new scientific partnership with the renowned Department of Pharmacological and Biomolecular Sciences of the Milan University (Università degli Studi di Milano) and the confirmation of collaboration with the Institute of Pharmacovigilance.
The EUPV Scientific Advisory Group has very clear that pharmacovigilance main pillars are:
• Safety Science – Regulatory compliance – Operational excellence
• Implementation of new technologies – Effective communication
All these aspects are reflected in the agenda of this year’s congress.
The EUPV congress gathers PV professionals at all career levels, including key decision makers (e.g. VPs, Executives and Directors) interested in the always evolving pharmacovigilance world and its new trends, since they are always looking for new ideas to implement more efficient and effective strategies and tools for their departments.
EUPV congress is the forum where all PV stakeholders from all over the world meet and exchange ideas.
PLEASE NOTE:
Ticket options labeled ‘+ Visa’ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
ANNUAL EUPV BOOKLET
The 3rd European Pharmacovigilance Congress: speaker abstracts 2019
The 4th European Pharmacovigilance Congress: speaker abstracts 2020
The 5th European Pharmacovigilance Congress: speaker abstracts 2021
The 6th European Pharmacovigilance Congress: speaker abstracts 2022
The 7th European Pharmacovigilance Congress: speaker abstracts 2023
The 8th European Pharmacovigilance Congress: speaker abstracts 2024
The 9th European Pharmacovigilance Congress: speaker abstracts 2025
Published by Sage Journals, visit their website here
Format del congresso
The European Pharmacovigilance Congress 2026 will be a mixed event!
November 18 | Virtual (9.00 – 5.30 pm)
November 19 | Virtual (9.00 – 6.00 pm)
December 3 | Milan* (3.00 – 7.00 pm) + Networking Aperitivo (7.00 – 9.00 pm)
December 4 | Milan* (9.15 – 5.30 pm)
* at NH Milan Congress Centre
NETWORKING APERITIVO December 3 (7.00 – 9.00 pm)
At the conference venue, PEC organizes a Networking Aperitivo that will take place together with interesting workshops. Reserve your place to meet and network with your colleagues and experts: Networking Aperitivo
The intense, scientific interaction between speakers and delegates is a further invaluable plus of the event:
– 27 Topics
– 24 round tables
– 7 virtual parallel sessions
– 1 LECTIO Magistralis
– 3 F2F parallel workshops
Why attend?
- Learn about the latest Pharmacovigilance trends and updates
- Share experiences and solutions at a leading European event
- Forge new collaborations with key decision makers
- Networking through the virtual platform with Pharma Companies Delegates and Speakers
Who should attend?
- Pharma, Biotech and Medical Devices Industries
- Pharmacovigilance Associations
- Regulatory Bodies
- CROs and CMOs
- Clinical Research Sites
- Data Management Companies
- Software Development Companies
- University Faculties
- PV Consultant Societies
AGENDA 2026
FEATURED TOPICS:
• DEVELOPMENTAL SAFETY FROM FIRST IN HUMAN TO MARKETING AUTHORIZATION APPLICATION
• PREDICT, PREVENT, PROTECT: TRANSLATIONAL SAFETY AS THE CATALYST FOR SMARTER RISK STRATEGIES
• SAFETY OF GENE THERAPIES AND RARE DISEASES
• SYNTHETIC DATA IN PHARMACOVIGILANCE: OPPORTUNITIES, RISKS AND REGULATORY REALITY
• NON-EU PV REQUIREMENTS (Africa, Asia, Americas, UK)
• DECISIONS THAT MATTER: REAL LIFE IMPACT OF DRUG SAFETY WORK
• SAFETY OF MEDICINES IN EARLY ACCESS PROGRAM
• SAFETY OF DRUGS USED IN HEPATIC RARE DISEASES
• SAFETY ASPECTS OF NEW PRODUCTS USED FOR THE TREATMENT OF INFLAMMATORY DISORDERS
• IMPACT OF NEW REGULATIONS AND GUIDELINES ON PV OPERATIONS
• REGULATORY REQUIREMENTS AND PRACTICAL EXEMPLES FOR IMPLEMENTING AI IN PV
• MEDICAL DEVICES & COMBINATION PRODUCTS SAFETY
• SAFETY INFORMATION FROM PATIENTS´PERSPECTIVE
• COSMETOVIGILANCE AND SAFETY OF NUTRACEUTICALS PRODUCTS
• EMA COMPUTERIZED SYSTEMS UPDATES
• ECOPHARMACOVIGILANCE
• PHARMACOEPIDEMIOLOGY AND REAL-WORLD EVIDENCE IN PHARMACOVIGILANCE: FROM SIGNAL TO DECISION
• RISK MANAGEMENT SYSTEMS
• WHAT IS AI AND ITS IMPLEMENTATION IN CASE PROCESSING
• HUMAN MACHINE INTERFACE IN PV
• SIGNAL DETECTION AND MANAGEMENT: THE USE OF RWD/RWE, THE USE OF AI AND POSSIBLE LIMITATIONS
• EFFICIENCY AND EFFECTIVENESS IN A RAPIDLY CHANGING PV LANDSCAPE
• MASTERING SAUDI/GCC PHARMACOVIGILANCE 2026
• PV AUDIT & INSPECTION
NOVEMBER 18 | VIRTUAL
In progress..
Translational safety is the science of predicting adverse reactions that may occur in humans by integrating preclinical and clinical data across drug development. Early and reliable prediction of risks associated with an investigational medicinal product can increase the likelihood of successful development and, most importantly, safeguards subjects participating in clinical trials.
In progress..
Pharmacovigilance outside the EU presents a highly dynamic regulatory landscape, shaped by local public‑health priorities and evolving legal frameworks. This session will take us across Asia and Africa, highlighting how global principles translate into regional practice. Pharmacovigilance systems must be reviewed to ensure alignment with these requirements.
The era of AI has paved the road to completely new possibilities that would have been unthinkable only a few years ago. This session looks into the near future by discussing the use of artificially generated datasets that mimic real drug-safety data.
While the methodologies to assess the risks of medicinal products are common throughout all therapeutic areas, each of them requires specific considerations. This session focuses on important safety aspects that have required investigation for new products indicated in inflammatory disorders
In progress..
SAFETY OF DRUGS USED IN HEPATIC RARE DISEASES (A DISCUSSION AT THE EUROPEAN PARLIAMENT)
A unique opportunity to hear first‑hand about a discussion held at one of Europe’s most important institutions, presented directly by the speaker involved sharing information that can be publicly disclosed.
SAFETY OF DRUGS USED IN HEPATIC RARE DISEASES (A DISCUSSION AT THE EUROPEAN PARLIAMENT)
A unique opportunity to hear first‑hand about a discussion held at one of Europe’s most important institutions, presented directly by the speaker involved sharing information that can be publicly disclosed.
NOVEMBER 19 | VIRTUAL
In progress..
In progress..
In progress..
AI has been a key buzzword in pharmacovigilance over recent years, yet its practical implementation remains a challenge. This session focuses on methodologies and real‑world examples that illustrate how AI can be effectively implemented in pharmacovigilance practice.
In progress..
In progress..
Pharmacovigilance professionals are often not fully aware of closely related disciplines, such as cosmetics and nutraceutical safety, and of the potential impact these products may have on drug safety. This session aims to provide an overview of these areas
All pharmacovigilance stakeholders, including regulators, are continuously enhancing their digital tools. This session enables participants to stay up to date with changes in EMA systems, such as EudraVigilance and the Clinical Trials Information System (CTIS).
In progress..
DECEMBER 3 | MILAN
The aim of pharmacovigilance is to identify the most important risks associated with a medicinal product and to minimise them, ensuring a positive benefit–risk balance. This session provides insights into how to establish an effective risk management system, including in particularly challenging situations.
The unprecedented volume of patient data available today offers new opportunities to transform data into meaningful evidence. Pharmacoepidemiology and real‑world evidence play a central role in identifying, quantifying, and characterizing risks, supporting more informed and robust regulatory decision‑making.
Many of us talk about AI without realizing it encompasses a range of different technologies, each with distinct characteristics, advantages, and limitations. This session introduces the fundamentals of AI and illustrates its practical application through a real‑life example in case processing.
BY IVIGEE
DECEMBER 4 | MILAN
In progress..
Pharmacovigilance is grounded in scientific disciplines such as biology and pharmacology, which underpin medicine safety from non‑clinical research through clinical development and shape risk management strategies. This session offers real‑world insights into the value of applying scientific principles to drug safety.
BY BAUPHARMA
Applying artificial intelligence to real‑world evidence is one of today’s most prominent topics. But what do regulators think? This session offers a rare opportunity to hear directly from PRAC members and leading scientists on how AI can be used to transform real‑world data into robust evidence for signal detection and management.
Featured presenters:
- Elena Alcaraz , EU/UK QPPV, Strategic Advisor | PrimeVigilance
- Mercedina del Papa, EU/UK QPPV, Strategic Advisor | PrimeVigilance
The session that traditionally closes the EU PV Congress is also one of its most important. Compliance -and the successful outcome of audits and inspections- represents the true “license to operate” in pharmacovigilance and across the pharmaceutical industry.
Scientific Advisory Group 2026
Felix Arellano
Senior Vice President and the Global Head of Safety & Risk Management | Roche
Ayman Ayoub
Vice President Safety Evaluation and Risk Management | GSK
Mattia Calissano
VP, Medical | SSI Strategy
Gian Nicola Castiglione
Pharmacovigilance Consultant, SIMeF ETS Board member, Past Head of Global Pharmacovigilance and EU-UK QPPV, Pharmacovigilance trainer
Manuela Casula
Associate Professor at Department of Pharmacological and Biomolecular Sciences | University of Milan
Mircea Ciuca
Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance
Giovanni Furlan
Head Medical Safety Operations | Sandoz
Calin A. Lungu
DDCS S.A., CEO
Hrvoje Maček
VP Pharmacovigilance Services | Clingen
Valentina Mancini
Senior Director Pharmacovigilance, QPPV | Shionogi Europe
Arduino Mangoni
Strategic Professor in Clinical Pharmacology | Flinders University, Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia
Jan Petracek
CEO | iVigee, Director | Institute of Pharmacovigilance
Marco Sardella
Chief Pharmacovigilance Officer & EU-UK QPPV| ADIENNE Pharma & Biotech
Ivana Šutalo
Innovative Products, Business Unit Lead / EU QPPV / LCPPV Croatia | PrimeVigilance Ltd.
SPEAKERS 2026 IN PROGRESS
Ana Sofia Martins
PRAC Member | INFARMED, I.P. – Portugal
Elena Giovani
Head of the GVP Inspection Office | AIFA (Tbc)
Amelia Cupelli
Pharmacologist, Italian Medicines Agency (AIFA), EMA PRAC Member, Italy
Pilar Rayón
PRAC – AEMPS Spain
Sophia Trantza
Senior Pharmacovigilance Expert, former PRAC Member Greece
Elena Prokofyeva
Head of Clinical Trial Safety Unit, Department of Pharmacovigilance, DG POST | FAMHP – Belgium
Lembit Rägo
Secretary-General | Council for International Organizations of Medical Sciences (CIOMS) – Switzerland
Ursula Kirchmayer
Pharmacoepidemiologist at the Department of Epidemiology | Lazio regional health service
Fazil Afzal
Senior Medical Assessor at Medicines and Healthcare products Regulatory Agency (MHRA) – Uk (tbc)
Michelle English
GCP/PV Inspector | HPRA – Ireland
Oanh Dang
Regulatory Science and Applied Research Lead | Food and Drug Administration (FDA) – USA
Marko Korenjak
President of the European Liver Patients ( ELPA), member of HMA management board of EMA – Slovenia
Maia Uusküla
Head of the Department of Post-Authorisation Safety | State Agency of Medicines, Estonia
Zane Neikena
PRAC – Latvia
Jens-Ulrich Stegmann
Senior Vice President, Head Clinical Safety and Pharmacovigilance and EU QPPV | GSK – Belgium
Jonathan Sutch
Principal Technical Specialist & Scheme Manager | BSI Group – UK
Axelle Mutezinkwano
Pharmacovigilance Analyst Team Lead | Rwanda Food and Drugs Authority
Annalisa Capuano
Full Professor of Pharmacology – Department of Experimental Medicine | University of Campania “L. Vanvitelli” – Italy
Kaori Nomura
Associate Professor | Fukushima Medical University – Japan
Andrew Bate
VP, Head of Safety Innovation & Analytics | GSK – Uk
Salvo Leone
General Director | Patient’s Association AMICI, Italy
Emanuele Lettieri
Full Professor | Politecnico of Milan, Italy
Margherita D'Antuono
EU-UK QPPV | Piramal Critical Care
Vicky Edwards
Vice President, Cross Therapeutic Area Safety Science, Global Patient Safety| Abbvie – UK
Anna Lombardo
Researcher | Istituto di Ricerche Farmacologiche Mario Negri IRCCS – Italy
Giovanna Paolone
Associate Professor of Pharmacology – Department of diagnostics and public health | University of Verona – Italy
Emanuela Corsini
Professor of Toxicology at Department of Pharmacological and Biomolecular Sciences ‘Rodolfo Paoletti’ | University of Milan
Barbara De Bernardi
EU & UK Pharmacovigilance Qualified Person, VP, Head of Global QPPV Office Worldwide Medical & Safety | Pfizer – Italy
Helaine Capucho
Access Director | Interfarma – Brazil
Ahmed Diaa Eldin
CEO | Baupharma – Czech Republic
Marie-Laure Kurzinger
Associate VP, Head of Pharmacoepidemiology -General Medicines, Pharmacovigilance and Patient Safety | Sanofi – France
Rajat Mohindra
Principal Medical Director Personalized Healthcare Safety | F.Hoffmann – La Roche – Switzerland
Adrian Roth
Principal Scientific Director Precision Safety | Roche – Switzerland
Ilaria Grisoni
Exec. Dir., Head of International QPPV Office, EEA QPPV | Jazz Pharmaceuticals – Italy
Michael Von Forstner
Managing Director | Mesa Laubela Consulting – Switzerland
Yiannoula Koulla
Patient Expert, Member of the EMA PRAC
Klaudija Marijanovic Barac
Associate VP, EU QPPV Deputy | Eli Lilly Hrvatska d.o.o. – Croatia
Daniela Gramaglia
Associate Director Medical Device Safety | Bayer
Alberto Gramaccioli
Director of Quality Management and Inspection | Pfizer
Maria Beatrice Panico
Chief Medical Officer | Scendea – UK
Maddalena Lino
Safety Risk Lead Director | Pfizer – Italy
Daniela Marcozzi
Head of Corporate Clinical Safety, Pharmacovigilance and R&D Compliance – Company Representative for Competent Health Authorities | Fidia Farmaceutici – Italy
Bogdana Ioana Balas
Group Medical Director | F. Hoffmann – La Roche Ltd – Switzerland
Lucia Biagiotti
Safety & Vigilance – BU Director | PL Italia
Alexandru Mihai Bica
Head of Early Development Safety | CSL Behring – Germany
Mehmet Burcu
Sr. Director, Epidemiology | Merck & Co., Inc., Rahway – NJ, USA
Marie-Pierre Caby-Tosi
Executive Director, EEA/UK QPPV, Head of EMEA PV Clinical Safety & Pharmacovigilance | Moderna – France
Katerina Georgousaki
Regulatory Affairs Manager | ELAIS-Unilever Hellas S.A. – Greece
Ramona Grigorescu
Senior Medical Monitor | Danone – Holland
Sadia Halim
SERM Medical Director | GSK – Uk
Daniel Hyde
Associate Director, Pharmacovigilance Operations | Clinigen – UK
Wojciech Masełbas
SERM Medical Director | Gsk – Poland
James Milligan
Vice President | SSI – UK
Darmendra Ramcharran
Sr Director, Safety & Quantitative Innovation | GSK – USA
Hendrik Šuvalov
PhD Student in Health Informatics | University of Tartu – Estonia
Alina Tudor
Senior Director, Pharmacovigilance | Kyowa Kirin International plc. – UK
Hans-Joerg Roemming
Executive Director, Head of RQS Information, Systems & Insights | Merck Healthcare KGaA
MEDIA PARTNER/COLLABORATIONS/SPONSORS 2026 - in progress
Sage Publishing
Scientific Media Partner
Sage Publishing
Scientific Media Partner
Published by Sage Publishing, Therapeutic Advances in Drug Safety (Impact Factor: 3.4) is an international peer-reviewed Open Access journal, delivering the highest quality original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in drug safety, providing an online forum for rapid dissemination of recent research and perspectives in this area.
As the official Media Partner of the European Pharmacovigilance Congress, Therapeutic Advances in Drug Safety will be publishing an online abstract supplement which will be free to access online.
For more information:
E-mail: shasha.sharief@sagepub.co.uk
Twitter: @TADrugSafety
Visit our website »
Institute of Pharmacovigilance
Collaboration
Institute of Pharmacovigilance
Collaboration
Founded in 2015, the Institute of Pharmacovigilance (IPV) is a not-for-profit, non-governmental global organization with a clear goal – to elevate the pharmacovigilance industry by competency and seniority certification.
In 2020, IPV partnered with the International Society of Pharmacovigilance (ISoP) to develop the Global Pharmacovigilance Professional Certification (GPPC), creating a globally recognized standard for PV professionals. The certification works with competency standards including knowledge, skills and attitudes suitable for every role in pharmacovigilance.
Committed to continuous innovation, IPV regularly updates its programs to reflect the latest advancements, ensuring certified professionals have practical knowledge and skills they can apply in their jobs immediately.
Visit our website »
Università degli Studi di Milano - Dipartimento di Scienze Farmacologiche e Biomolecolari
Scientific Partnership
Università degli Studi di Milano - Dipartimento di Scienze Farmacologiche e Biomolecolari
Scientific Partnership
Il Dipartimento di Scienze Farmacologiche e Biomolecolari “Rodolfo Paoletti” (DiSFeB), nominato Dipartimento di Eccellenza 2023-2027, nasce il 27 aprile 2012 dall’aggregazione di settori scientifico disciplinari con comuni interessi di ricerca scientifica di alto profilo, e assicura un’equilibrata valorizzazione di tutti i settori scientifico-disciplinari che vi afferiscono. Il DiSFeB mira a consolidare il suo ruolo chiave nelle attività didattiche e di ricerca, e a rinnovare il suo portfolio di competenze tecnico-scientifiche a beneficio della società, contribuendo nel campo delle scienze biologiche applicate alla salute umana, alla prevenzione delle malattie e alla progettazione di farmaci e prodotti per la salute.
Visit our website »
Baupharma
Silver Sponsor
Baupharma
Silver Sponsor
Baupharma, headquartered in Prague, is a premier pharmaceutical service provider with over 25 years of industry experience. Our international team offers comprehensive services—including pharmacovigilance, regulatory affairs, medical writing, batch release and distribution, translations, and clinical research—across the EU, MENA region, CIS, Africa, USA, LATAM, and beyond. With offices in Czech Republic, Saudi Arabia, UAE and Egypt, we ensure efficient project management and collaboration, delivering tailored solutions that meet the unique needs of each market.
Visit our website »
Eureka InfoMed
Exhibitor
Eureka InfoMed
Exhibitor
Eureka InfoMed – Your Team to Growth
We make Pharmacovigilance work — reliably, efficiently, and with purpose.
Eureka InfoMed is a trusted partner delivering end‑to‑end operational support across Pharmacovigilance, Medical Information, and Quality.
We combine operational excellence with a pragmatic, partnership‑driven approach to turn complexity into compliant, efficient, and scalable processes.
Within these areas, we support pharmaceutical and biotech companies through services including Quality Management Systems, Quality Assurance activities, and Pharmacovigilance audits, helping them strengthen compliance, mitigate risk, and optimize operations in a constantly evolving regulatory environment.
We don’t believe in one‑size‑fits‑all solutions.
Whether you are building, strengthening, or transforming your Pharmacovigilance organization, Eureka InfoMed works side by side with you, acting as an extension of your team and providing expertise that grows with your needs and strategic objectives.
Visit our website »
Insuvia
Exhibitor
Insuvia
Exhibitor
Insuvia is designed to act as a pharmacovigilance unit for pharmaceutical companies in those countries and regions, where they have no internal structures or decide to focus their resources on commercial activities. In this context, we provide the regional EU and country-level expertise to solve all pharmacovigilance challenges that pharmaceutical companies encounter while commercializing their products.
Visit our website »
iVigee
Platinum Sponsor
iVigee
Platinum Sponsor
iVigee is a leading pharmacovigilance services and technology company focused on creating simple, powerful, and elegant drug safety solutions that span the entire drug safety life cycle.
We combine years of experience with the latest innovative AI technologies to create the ‘instant pharmacovigilance department’, deployable anywhere, on-demand.
Our teams support clients around the world with progressive pharmacovigilance and data management requirements from our strategic bases in Central Europe and the US East Coast.
iVigee: Simple. Powerful. Elegant.
Visit our website »
Max Application
Exhibitor
Max Application
Exhibitor
SafetyDrugs, developed by Max Application, an Abacus company, is a pharmacovigilance safety database managing the lifecycle of ICSRs from clinical trials and post-marketing sources. Designed in compliance with ICH E2B(R3), GVP and GDPR, it meets EMA, FDA and MHRA requirements. The platform enables automated case transmission and regulatory reporting (PSUR, PBRER, DSUR), ensuring data integrity, inspection readiness and full compliance. The offering is completed by the Business Intelligence module for Signal Detection and by the newly developed Chronisia, which automatically calculates regulatory deadlines (e.g. PSUR, RMP, MA renewal) enables task assignment and reduces risk of delays and non-compliance.
Visit our website »
PrimeVigilance
Gold Plus Sponsor
PrimeVigilance
Gold Plus Sponsor
PrimeVigilance, an Ergomed company, has grown to become the leading Pharmacovigilance specialist company, delivering global solutions for clinical safety and post-marketing pharmacovigilance and medical information from our operational hubs based in Europe, the USA, and Japan. Our extensive experience enables us to offer a comprehensive, top-quality, cost-effective, and innovative safety solution. Our flexible approach, tailor-made to work with clients, allows us to deliver the services that meet your clinical and post-marketing needs. PrimeVigilance provides pharmacovigilance solutions to over 300 clients who distribute their products worldwide. PrimeVigilance manages a global Pharmacovigilance system with a choice of leading drug safety databases, stretching to more than 100 countries.
Visit our website »
ProductLife Group
Exhibitor
ProductLife Group
Exhibitor
ProductLife Group’s mission is to improve human health by delivering regulatory compliance services that support the safe and effective use of healthcare products and solutions.
For more than 30 years, PLG has supported clients throughout the entire product lifecycle, combining local expertise with a global reach spanning more than 150 countries. The Group provides consulting and outsourcing services across regulatory affairs, quality and compliance, market access, pharmacovigilance, and medical information, covering both established products and innovative therapeutics and diagnostics.
Committed to continuously improving the value delivered to patients and customers, PLG fosters long-term partnerships built on innovation, flexibility, and cost efficiency.
Visit our website »
PVpharm
Gold Sponsor
PVpharm
Gold Sponsor
Pharmacovigilance, Clinical Safety, Regulatory and Quality Solutions for the pharmaceutical industry.
PVpharm provides services to Marketing Authorisation Holders, Sponsors of Clinical Trials and other Life science service providers.
Our objective is to help the Pharmaceutical industry to comply with Pharmacovigilance, Clinical safety, Regulatory and Quality requirements. We provide global, professional, quick, and flexible solutions to complex, specialized needs.
Our specialities include Pharmacovigilance and Clinical Safety services, Regulatory affairs, Medical Services, EU-QPPV and Local contact person for pharmacovigilance, Pharmacovigilance and GCP Audits, EudraVigilance compliance, CTIS support, Pharmacovigilance training, including EVWeb and XEVMPD (eXtended EudraVigilance Medicinal Product Dictionary) training, Signal Detection and Signal Management using EVDAS, IDMP implementation preparation, and data management.
We provide services for drugs, devices, veterinary, food supplements and cosmetics.
We do also provide GxP support and provide GMP specialized audits.
Visit our website »
Become a sponsor
Don’t miss the chance to be a European Pharmacovigilance Congress 2026 sponsor!
Contact us to learn about our sponsorship packages, you will have the opportunity to:
• Deliver a talk in person or online
• Conduct a parallel session during the day in Milan
• Network and connect with your target customers
Check out our sponsorship opportunities here: Become EUPV Sponsor
Conference Venue
Step 1
On November 18-19 the event will be VIRTUAL to grant you the possibility of joining the conference even from your office or home, wherever you may be. We have organized a true virtual location, a space where you will be able to:
- Follow the live streaming of the congress, listen to experts and opinion makers and be informed about latest trends and technological breakthroughs in drug safety
- Visit the VIRTUAL EXHIBITION AREA and all the stands of our sponsors
- Join Q&A times and round tables to discuss the current hot topics in the field
- Chat with our sponsors and learn about new technologies and services to ease your daily work and increase the performance
Step 2
Let’s finally meet face to face in Milan on December 3-4! A great chance to meet in person the EUPV experts and colleagues. A great chance to meet in person the EUPV experts and colleagues. The conference will be hosted in the wonderful spaces of NH Milano Congress Centre, in Assago, Milan.
NETWORKING APERITIVO December 3, 2026 (NH Milano Congress Centre, in Assago, Milan)
–> If you would like to attend the Networking Aperitivo, please save your spot here: Networking Aperitivo
PLEASE NOTE:
Ticket options labeled ‘+ Visa’ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
By plane
From Malpensa Airport:
-
- take the bus to the central station, then the subway towards Assago Milanofiori Forum
- take the express train from Malpensa to the Cadorna station, then the Green subway in the direction of Assago Milanofiori Forum.
From Linate Airport:
take the bus to San Babila station, then the subway towards Assago Milanofiori Forum.
By train
From Centrale or Cadorna train station, take green line subway to Assago Milanofiori Forum.
By tram
From Piazza del Duomo:
take the red subway line towards RHO FIERAMILANO and change at CADORNA. Take the green line towards ASSAGO MILANOFIORI FORUM and get off at the Assago Milanofiori Forum stop. Walk for about 7 minutes to reach the hotel.
All the past editions
Sign up for the conference
Face to Face (3-4/12/2026) | 450€ |
Virtual (18-19/11/2026) | 750€ |
Virtual + Face to Face (18-19/11/2026 and 3-4/12/2026) | 880€ |
If you would like to attend the NETWORKING APERITIVO, please save your spot here: Networking Aperitivo
Attendance to the event will be allowed upon receipt of payment.
* Hospitals, Universities and freelancers get a 40% discount on published prices (discounts cannot be combined).